港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议多条研发管线即将进入产品收获期

智通财经10-10

智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.69%，报49.1港元，成交额2.69亿港元。消息面上，近日，信达生物与奥赛康药业签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。据悉，国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请。天风证券指出，2024H1信达生物总收入...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2474327417?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-10 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474327417","market":"hk","top_or_hot":-1,"title":"港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.69%，报49.1港元，成交额2.69亿港元。消息面上，近日，信达生物与奥赛康药业签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。据悉，国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请。天风证券指出，2024H1信达生物总收入...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1192151.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 10:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1192151.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.69%，报49.1港元，成交额2.69亿港元。消息面上，近日，信达生物与奥赛康药业签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。据悉，国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请。天风证券指出，2024H1信达生物总收入...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1192151.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1192151.html","article_id":"2474327417","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474327417","pubTimestamp":1728526637,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，信达生物涨超3%，截至发稿，涨3.69%，报49.1港元，成交额2.69亿港元。消息面上，近日，信达生物与奥赛康药业签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物“利厄替尼片”达成独家商业化合作。据悉，国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请。天风证券指出，2024H1信达生物总收入为39.5亿元，同比增长46.3%；产品收入38.1亿元，同比增长55.1%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK0028":"国家队","002755":"奥赛康","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01801":"信达生物","BK1589":"北水核心资产","BK1161":"生物科技","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"Changes in Hong Kong stocks Innovent Biologics (01801) rose more than 3% Recently signed a cooperation agreement with Osaikang Pharmaceutical, and multiple R&D pipelines are about to enter the product harvest period","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002755":1,"01801":1},"content_text":"智通财经APP获悉，信达生物(01801)涨超3%，截至发稿，涨3.69%，报49.1港元，成交额2.69亿港元。消息面上，近日，信达生物与奥赛康药业签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。据悉，国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请。天风证券指出，2024H1信达生物总收入为39.5亿元，同比增长46.3%；产品收入38.1亿元，同比增长55.1%。公司产品连续多个季度同比高速增长。考虑到公司已上市产品持续放量，多条研发管线即将进入产品收获期，该行将公司2024和2025年的收入预期分别从72.25、91.93亿元上调至79.70、102.35亿元，预计2026年收入将达到131.43亿元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474327417"}

港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议 多条研发管线即将进入产品收获期

精彩评论

港股异动 | 信达生物(01801)涨超3% 近日与奥赛康药业签订合作协议多条研发管线即将进入产品收获期